{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-027967","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.884433+00:00","generated_at":"2026-06-22T08:51:30.979700+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"X4 Pharma Q3 net loss $21.6M; Phase 3 WHIM data on track for Q4; CMO departure, CCO appointed","bullets":["Net loss of $21.6M for Q3 2022, vs $20.2M in Q3 2021; cash $81.1M as of Sept 30, 2022, sufficient into Q3 2023.","R&D expenses $14.1M, SG&A $6.0M; PIPE financing gross proceeds $55M in July 2022.","Phase 3 4WHIM trial top-line data anticipated Q4 2022; NDA submission early H2 2023 if positive.","Positive Phase 1b data for mavorixafor in chronic neutropenia; trial expanding to Phase 1b/2 in H1 2023.","Mark Baldry appointed CCO; CMO Diego Cadavid to resign by end of 2022, Dr. Murray Stewart interim CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-027967","json":"https://secwatch.observer/filing/0001628280-22-027967.json","markdown":"https://secwatch.observer/filing/0001628280-22-027967.md","text":"https://secwatch.observer/filing/0001628280-22-027967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022027967/0001628280-22-027967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022027967/xfor-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:51:30.979700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ae2e4d67754faaf6af5b7014792c96c5e8e17b3","claim":"X4 Pharmaceuticals, Inc reported the third quarter ended September 30, 2022 results: net income $21.6 million.","evidence_excerpt":"X4 reported a net loss of $21.6 million for the third quarter of 2022, as compared to $20.2 million for the comparable period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022027967/0001628280-22-027967-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$21.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}